With the exclusive collaboration and licensing agreement announced in November 2018, Zai Lab and MacroGenics won the “Deal of the Year” award at the 10th China Healthcare Investment Conference (CHIC) in Shanghai on March 27th, 2019. The award commends cross-border deals in the Chinese healthcare industry, including collaboration, technology transfer, authorization, funding, merger and joint venture projects, where Chinese companies are involved.
Dr. James Yan (left), Executive Vice President and Head of Pre-Clinical Development and Program & Portfolio Management of Zai Lab attended the ceremony.
The revolution and development of the healthcare industry fueled the current wave of emerging healthcare companies in China. Leading healthcare investors took the opportunity to create CHIC in 2010. Over the past 10 years, the conference has become the most influential platform for the promotion and exchanges of innovative biomedicines in China. Not only has CHIC improved the healthcare investment ecosystem in China, it has advanced the development of the industry on a large scale. CHIC has been accredited as the Chinese version of the “J.P. Morgan Healthcare Conference”.
In November 2018, Zai Lab and MacroGenics, a US biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced their exclusive collaboration and licensing agreement for three immuno-oncology (I-O) programs from MacroGenics, including: Margetuximab, an immune-optimized anti-HER2 monoclonal antibody (“Marge”); MGD013, a first-in-class bispecific DART® molecule; and an undisclosed multi-specific TRIDENT™ molecule in preclinical development.
In February 2019, MacroGenics announced that the phase III SOPHIA clinical trial has shown Margetuximab to improve progression-free survival (PFS) compared to HERCEPTIN® (trastuzumab), when used in combination with chemotherapy in patients with HER2+ metastatic breast cancer.
It is notable that in the selection of the “Deal of the Year” award, Zai Lab held 2 of the 7 nominated deals with the strategic collaboration with MacroGenics and Novocure.
Dr. Samantha Du, Founder and CEO of Zai Lab, stated that: “This is a great honor for Zai Lab, and it highlights the ingenuity of our business development and execution teams to identify innovative drugs. It further demonstrates the extensive expertise and rich experience of Zai Lab in collaboration. Zai Lab could be considered as a best partner for innovative products seeking to enter China. We will continue to drive the development of Margetuximab in China and the world so that “Marge” can benefit the 70,000 HER2-positive breast cancer patients and 90,000 HER2-positive gastric cancer patients in China as soon as possible.”
On the morning of March 27, Dr. Samantha Du was invited as a guest of honor at the main forum of CHIC, together with Ms. Lu Hongbo, co-founder of CHIC and managing partner of Lilly Asia Ventures, to discuss the development of China's biopharmaceutical industry in the past decade and its future prospects.
Dr. Samantha Du (right), Founder and CEO of Zai Lab, on CHIC